C4 Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
CCCC$3.15+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $126,590 | $29,754 |
| Marketable securities, current | 127,091 | 246,399 |
| Accounts receivable | 11,799 | 1,473 |
| Prepaid expenses and other current assets | 5,709 | 9,931 |
| Total current assets | 271,189 | 287,557 |
| Marketable securities, non-current | 28,008 | 60,962 |
| Property and equipment, net | 7,132 | 7,400 |
| Right-of-use asset | 63,956 | 70,116 |
| Restricted cash | 3,443 | 3,279 |
| Other assets | 2,723 | 1,526 |
| Total assets | $376,451 | $430,840 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,446 | $1,172 |
| Accrued expenses and other current liabilities | 20,630 | 19,769 |
| Deferred revenue, current | 15,471 | 16,618 |
| Operating lease liability, current | 5,219 | 4,700 |
| Long-term debt, net of debt discount—related party, current | — | 2,287 |
| Total current liabilities | 42,766 | 44,546 |
| Deferred revenue, net of current | 21,814 | 16,895 |
| Operating lease liability, net of current | 65,757 | 70,970 |
| Long-term debt, net of debt discount—related party, net of current | — | 9,195 |
| Total liabilities | 130,337 | 141,606 |
| Commitments and contingencies (See Note 6 and Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of December 31, 2023 and 2022, respectively | — | — |
| Common stock, par value of $0.0001 per share; 150,000,000 shares authorized, and 60,467,188 and 48,966,216 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 6 | 5 |
| Additional paid-in capital | 774,618 | 689,256 |
| Accumulated other comprehensive loss | (127) | (4,137) |
| Accumulated deficit | (528,383) | (395,890) |
| Total stockholders’ equity | 246,114 | 289,234 |
| Total liabilities and stockholders’ equity | $376,451 | $430,840 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.